HealthScape Advisors, a healthcare payer consulting firm operating under the Chartis umbrella, acquired PayerAlly, with the goal of helping health plans and employers control rising prescription drug spending. Financial terms were not disclosed.
A Deal Aimed at Specialty Drug Costs
The acquisition integrates PayerAlly’s specialization in PBM procurement and specialty pharmacy optimization into HealthScape’s existing advisory services. The combined firm will offer clients a more unified approach to total cost-of-care management, drawing on both medical and pharmacy data analytics.
“Payers are under increasing pressure to manage rising pharmacy costs while improving outcomes and member experience,” said Dan Delaney, Managing Partner at HealthScape Advisors. “PayerAlly brings deep, specialized expertise in PBM and specialty pharmacy strategy that complements our broader payer capabilities.”
Specialty therapies and infusion drugs are increasingly viewed as major contributors to healthcare spending growth, pushing health plans to seek independent advisors who can audit vendor contracts and dissect complex rebate structures.
PayerAlly’s Role and Leadership Structure
Founded in 2022 and headquartered across offices in Orlando and New York City, PayerAlly will operate as a division of HealthScape rather than a fully absorbed unit. Its founding leadership team, Will McHugh, Bill Guerci, and Kerri Tanner, will remain in place to manage the subsidiary’s operations.
“Joining HealthScape enables us to accelerate our mission, combining our analytics and pharmacy expertise with their deep payer insight,” the PayerAlly leadership said in a joint statement. The firms said they plan to develop technology-enabled tools to help clients audit vendor performance and optimize drug pricing strategies.
PBMs Control Most of the U.S. Prescription Market
The deal reflects growing demand for independent PBM advisory services in a market dominated by a handful of large benefit managers. Industry estimates suggest PBMs manage the vast majority of prescription drug claims in the United States, creating a need for health plans and self-insured employers to bring in outside consultants who can evaluate terms, benchmark pricing, and identify where rebates may not be passing through to the payer.
That concentration gives PBMs substantial leverage in contract negotiations, particularly as employers and insurers look for greater transparency around specialty drug pricing and rebate arrangements.
Part of a Broader Chartis Expansion
The PayerAlly acquisition fits a pattern of deliberate growth at Chartis, HealthScape’s parent company. HealthScape became part of Chartis in 2024 to strengthen the firm’s advisory capabilities on the payer side of the healthcare market.
HealthScape serves commercial, Medicare, and Medicaid health plans from its Chicago headquarters. With PayerAlly now operating as a division within HealthScape, the firm says it is better positioned to serve progressive employers and ancillary health organizations seeking pharmacy cost transparency.
What remains to be seen is how quickly the joint team can bring its planned audit and pricing tools to market and whether the combined practice can meaningfully move the needle on specialty drug spending for its clients.
